Addentax Group Corp. Announces Strategic Cooperation Discussions with KINGS UNITED to Advance Web3.0 and RWA Initiatives - Addentax Group (NASDAQ:ATXG)

ADDENTAX GROUP CORP. (ATXG) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001650101 0001650101 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Combined BHP Ports Unions will seek arbitration with BHP over a wage deal dispute for Port Hedland iron ore operations. The union, representing 450 workers, seeks a four-year agreement, while BHP offered a 17% pay increase and A$25,000 transition payment. The union claims 40% of workers would be worse off under BHP's proposal.

Sempra Infrastructure signed a 20-year LNG supply deal with Petrobras for 800,000 tonnes per year, sourced from its Port Arthur LNG Phase 2 project in Texas. The agreement adds Petrobras as Sempra's first South American LNG customer. Port Arthur Phase 2, with a $14 billion estimated cost, is set to add 13 million tonnes per annum of liquefaction capacity and begin operations in 2030-2031. Sempra has previously secured LNG agreements with ConocoPhillips, JERA, and EQT for Phase 2.

Novartis' pelacarsen and Novo Nordisk's ziltivekimab failed in Phase 3 trials, testing different cardiovascular risk theories. Both drugs did not reduce cardiovascular events despite lowering targets. Novartis reported pelacarsen's Lp(a)HORIZON trial results, while Novo Nordisk halted ziltivekimab's HERMES and ATHENA trials. Analysts estimated pelacarsen's peak sales at $4B-$6B. Both companies have other trials ongoing.

Santos has signed two LNG agreements: a 10-year supply deal with POSCO Steel and a 20-year purchase agreement with Western LNG for 1 million metric tons per year, starting around 2031.

Oppenheimer increased its price target for Definium Therapeutics (DFTX) to $75 from $70, maintaining an Outperform rating. The firm cited positive Phase 3 trial results for DT120, which it believes support the company's potential to improve treatment for GAD patients. Oppenheimer updated its model to reflect increased optimism.